[{"address1": "2929 7th Street", "address2": "Suite 105", "city": "Berkeley", "state": "CA", "zip": "94710", "country": "United States", "phone": "510 982 6030", "website": "https://cariboubio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.", "fullTimeEmployees": 147, "companyOfficers": [{"maxAge": 1, "name": "Dr. Rachel E. Haurwitz Ph.D.", "age": 38, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1986, "fiscalYear": 2024, "totalPay": 832920, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Timothy P. Kelly M.B.A.", "age": 55, "title": "Chief Technology Officer", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 730050, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Barbara G. McClung Esq., J.D.", "age": 69, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1955, "fiscalYear": 2024, "totalPay": 668622, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sriram  Ryali M.B.A.", "age": 43, "title": "Chief Financial Officer", "yearBorn": 1981, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Poon", "title": "Vice President of Operations & Information Technology", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Fischesser", "title": "Interim Principal Accounting Officer & Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amy  Figueroa C.F.A.", "title": "Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Reigin  Zawadzki", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ruhi A. Khan M.B.A.", "age": 49, "title": "Chief Business Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 573900, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tina  Albertson M.D., Ph.D.", "age": 51, "title": "Chief Medical Officer", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.84, "open": 1.84, "dayLow": 1.825, "dayHigh": 1.965, "regularMarketPreviousClose": 1.84, "regularMarketOpen": 1.84, "regularMarketDayLow": 1.825, "regularMarketDayHigh": 1.965, "payoutRatio": 0.0, "beta": 2.555, "forwardPE": -0.9296482, "volume": 1394084, "regularMarketVolume": 1394084, "averageVolume": 1621053, "averageVolume10days": 993790, "averageDailyVolume10Day": 993790, "bid": 1.82, "ask": 1.89, "bidSize": 2, "askSize": 2, "marketCap": 172277920, "fiftyTwoWeekLow": 0.66, "fiftyTwoWeekHigh": 3.0, "priceToSalesTrailing12Months": 18.888052, "fiftyDayAverage": 1.7256, "twoHundredDayAverage": 1.4646, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 14180992, "profitMargins": 0.0, "floatShares": 84057692, "sharesOutstanding": 93123200, "sharesShort": 3895329, "sharesShortPriorMonth": 6189594, "sharesShortPreviousMonthDate": 1751241600, "dateShortInterest": 1753920000, "sharesPercentSharesOut": 0.0419, "heldPercentInsiders": 0.09814999, "heldPercentInstitutions": 0.42298, "shortRatio": 2.09, "shortPercentOfFloat": 0.043899998, "impliedSharesOutstanding": 93123200, "bookValue": 1.784, "priceToBook": 1.0369955, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -164263008, "trailingEps": -1.78, "forwardEps": -1.99, "enterpriseToRevenue": 1.555, "enterpriseToEbitda": -0.097, "52WeekChange": -0.16289592, "SandP52WeekChange": 0.1513431, "quoteType": "EQUITY", "currentPrice": 1.85, "targetHighPrice": 32.0, "targetLowPrice": 1.0, "targetMeanPrice": 8.85714, "targetMedianPrice": 5.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 183948000, "totalCashPerShare": 1.975, "ebitda": -146260992, "totalDebt": 25851000, "quickRatio": 6.464, "currentRatio": 6.664, "totalRevenue": 9121000, "debtToEquity": 15.561, "revenuePerShare": 0.099, "returnOnAssets": -0.31775, "returnOnEquity": -0.68931997, "grossProfits": -119863000, "freeCashflow": -79720248, "operatingCashflow": -133114000, "revenueGrowth": -0.23, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -13.28384, "financialCurrency": "USD", "symbol": "CRBU", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Caribou Biosciences, Inc.", "longName": "Caribou Biosciences, Inc.", "marketState": "CLOSED", "regularMarketChangePercent": 0.543478, "regularMarketPrice": 1.85, "corporateActions": [], "postMarketTime": 1755901846, "regularMarketTime": 1755892800, "exchange": "NMS", "messageBoardId": "finmb_272189231", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1627047000000, "postMarketChangePercent": -0.54054004, "postMarketPrice": 1.84, "postMarketChange": -0.00999999, "regularMarketChange": 0.00999999, "regularMarketDayRange": "1.825 - 1.965", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1621053, "fiftyTwoWeekLowChange": 1.19, "fiftyTwoWeekLowChangePercent": 1.8030304, "fiftyTwoWeekRange": "0.66 - 3.0", "fiftyTwoWeekHighChange": -1.15, "fiftyTwoWeekHighChangePercent": -0.38333333, "fiftyTwoWeekChangePercent": -16.289593, "earningsTimestampStart": 1762977600, "earningsTimestampEnd": 1762977600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.78, "epsForward": -1.99, "epsCurrentYear": -1.64, "priceEpsCurrentYear": -1.1280488, "fiftyDayAverageChange": 0.12440002, "fiftyDayAverageChangePercent": 0.07209088, "twoHundredDayAverageChange": 0.38540006, "twoHundredDayAverageChangePercent": 0.26314357, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-07-23", "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "market": "us_market", "esgPopulated": false, "displayName": "Caribou Biosciences", "trailingPegRatio": null, "__fetch_time": "2025-08-23"}]